Indegene gets Sebi nod to float IPO

economictimes.indiatimes.com:

IPO papers with Sebi in December 2022 The IPO of Indegene consists of a fresh issue of equity shares worth up to Rs 950 crore and offer for sale (OFS) of up to 3.63 crore equity shares by existing investors, according to the Draft Red Herring Prospectus (DRHP). The OFS consists of up to 27 lakh equity shares to be sold by individual selling shareholders — Manish Gupta, Rajesh Bhaskaran Nair, and Anita Nair — and up to 3.36 crore equity shares by existing investors, including Carlyle, Brighton Park Capital and the Nadathur Family Office.

The funds raised through the fresh issue would be used to pay debt, fund capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, fund inorganic growth and general corporate purposes Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle. The company reported revenue from operations of Rs 1,665 crore in FY2021-22 and posted a profit after tax of Rs 163 croreKotak Mahindra Capital, Citigroup Global Markets India, J P Morgan India, Nomura Financial Advisory and Securities (India) are the book running lead managers to the issue.